Table 1.
Lead author | Yr | n | Location of tumor thrombus | Treatment | Mortality within 1 mo (%) | Response rate (%) | Median survival time (mo) |
Yamada R et al[9] | 1983 | 9 | Vp4 | TACE | 55.5 | - | - |
Okazaki M et al[10] | 1991 | 48 | Vp2 | TACE | 6.5 | - | 4.3 |
56 | Vp3 | TACE | 8 | - | 4 | ||
59 | Vp4 | TACE | 5.6 | - | 3.8 | ||
Raoul JL et al[14] | 1994 | 27 | Vp3, 4 | 131I-labeled lipiodol | 0 | 40 | 6 |
Chung JW et al[12] | 1995 | 110 | Vp3, 4 | TACE | 2.7 | 28 | 6 |
Georgiades CS et al[13] | 2005 | 32 | Vp3, 4 | TACE | 0 | - | 9.5 |
Vp2: 2nd order branches of the portal vein; Vp3: 1st order branches of the portal vein; Vp4: the main trunk of the portal vein.